• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
GSS
Click for more information
3.50% 69.0¢

GENETIC SIGNATURES LIMITED - Announcements

Market Cap $155.4M  ! watchlist Created with Sketch. Add to my watchlist

Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx)... Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company's principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit, and others. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
GSS Appendix 3B27/03/19
GSS Change of Director's Interest Notice22/03/19
GSS Appendix 3B22/03/19
GSS Investor Presentation15/03/19
GSS Change of Company Secretary and Registered Address04/03/19
GSS Half Yearly Report and AccountsPRICE SENSITIVE25/02/19
GSS Appendix 4C - quarterlyPRICE SENSITIVE29/01/19
GSS CE-IVD Mark for Respiratory Pathogen Detection KitPRICE SENSITIVE17/12/18
GSS Becoming a substantial holder14/12/18
GSS $2.6m R&D refund receivedPRICE SENSITIVE07/12/18
GSS Ceasing to be a substantial holder07/12/18
GSS Becoming a substantial holder05/12/18
GSS Change of Director's Interest Notice03/12/18
GSS Appendix 3B03/12/18
GSS Results of Annual General Meeting29/11/18
GSS Chairman's Address to ShareholdersPRICE SENSITIVE29/11/18
GSS Withdrawal of resolution 4 from 2018 Annual General Meeting29/11/18
GSS Investor presentationPRICE SENSITIVE26/11/18
GSS Ceasing to be a substantial holder22/11/18
GSS Becoming a substantial holder21/11/18
GSS Appendix 3B19/11/18
GSS Appendix 3B15/11/18
GSS Notice of Annual General Meeting/Proxy Form29/10/18
GSS 2018 Annual Report to Shareholders29/10/18
GSS Appendix 4C - quarterlyPRICE SENSITIVE29/10/18
GSS Appendix 3B22/10/18
GSS Appointment of CFO22/10/18
GSS Date of 2018 AGM17/09/18
GSS Appendix 4G and 2018 Corporate Governance Statement28/08/18
GSS Appendix 4E and 2018 Financial ReportPRICE SENSITIVE28/08/18
GSS Additional Tax Incentive from understatement FY17 R&D ClaimPRICE SENSITIVE23/08/18
GSS Investor PresentationPRICE SENSITIVE15/08/18
GSS Update to major customer contract announcementPRICE SENSITIVE03/08/18
GSS Major Customer Contract Signed, New Kit and InstrumentPRICE SENSITIVE02/08/18
GSS Appendix 4C - quarterlyPRICE SENSITIVE27/07/18
GSS Investor PresentationPRICE SENSITIVE23/05/18
GSS TGA registration for superbug detection kitsPRICE SENSITIVE15/05/18
GSS Investor Newsletter07/05/18
GSS Positive Trial Results Presented at ECCMIDPRICE SENSITIVE26/04/18
GSS Appendix 4C - quarterlyPRICE SENSITIVE26/04/18
GSS European approval expands product suite20/04/18
GSS Change of Director's Interest Notice10/04/18
GSS Appendix 4D and Half Year Financial StatementsPRICE SENSITIVE28/02/18
GSS Appendix 4C - quarterlyPRICE SENSITIVE25/01/18
GSS Change of Director's Interest Notice19/12/17
GSS Appendix 3B11/12/17
GSS Change of Principal Place of Business address11/12/17
GSS Results of 2017 AGM28/11/17
GSS 2017 AGM PresentationPRICE SENSITIVE28/11/17
GSS Clarification of Change in Substantial Shareholding24/11/17
GSS Change in substantial holding24/11/17
GSS Appendix 4C - quarterlyPRICE SENSITIVE30/10/17
GSS Notice of Annual General Meeting/Proxy Form27/10/17
GSS Annual Report to shareholders27/10/17
GSS Change of Director's Interest Notice19/09/17
GSS Notification of 2017 AGM date15/09/17
GSS Appendix 4G and 2017 Corporate Governance Statement30/08/17
GSS Appendix 4E and 2017 Financial ReportPRICE SENSITIVE30/08/17
GSS Appendix 3B02/08/17
GSS Investor Presentation26/07/17
GSS Appendix 4C - quarterlyPRICE SENSITIVE25/07/17
GSS Appendix 3B11/07/17
GSS Change of Director's Interest Notice30/06/17
GSS Regulatory and Patent approvalPRICE SENSITIVE20/06/17
GSS Appendix 4C - quarterlyPRICE SENSITIVE28/04/17
GSS Results of Flavivirus Clinical TrialPRICE SENSITIVE24/04/17
GSS Ceasing to be a substantial holder31/03/17
GSS GSS Launches Sexually Transmitted Infection (STI) KitPRICE SENSITIVE31/03/17
GSS End of escrow period15/03/17
GSS Change of Director's Interest Notice10/03/17
GSS Appendix 4D - Half Yearly Report and AccountsPRICE SENSITIVE27/02/17
GSS Appendix 3B23/02/17
GSS Appendix 4C - quarterlyPRICE SENSITIVE31/01/17
GSS Change of Director's Interest Notice22/12/16
GSS Appendix 3B21/12/16
GSS Change of Director's Interest Notice05/12/16
GSS Appendix 3B30/11/16
GSS Results of Meeting29/11/16
GSS 2016 AGM MD and CEO PresentationPRICE SENSITIVE29/11/16
GSS Chairman's Address to ShareholdersPRICE SENSITIVE29/11/16
GSS Annual Report to shareholders-GSS.AX 28/10/16
GSS Notice of Annual General Meeting/Proxy Form-GSS.AX 28/10/16
GSS Appendix 4C - quarterly-GSS.AX PRICE SENSITIVE28/10/16
GSS Change in substantial holding-GSS.AX 24/10/16
GSS Change in substantial holding-GSS.AX 24/10/16
GSS Change of Director's Interest Notice-GSS.AX 24/10/16
GSS Becoming a substantial holder-GSS.AX 20/10/16
GSS Cleansing Notice-GSS.AX 19/10/16
GSS Appendix 3B-GSS.AX 19/10/16
GSS STI Detection Kit Clinical Validation Trial Results-GSS.AX PRICE SENSITIVE18/10/16
GSS Microcap Investment Conference Presentation-GSS.AX 18/10/16
GSS Results of EGM-GSS.AX 13/10/16
GSS Change in substantial holding-GSS.AX 11/10/16
GSS Change of Director's Interest Notice-GSS.AX 10/10/16
GSS Change of Director's Interest Notice-GSS.AX 10/10/16
GSS Appendix 3B - SPP allotment-GSS.AX 06/10/16
GSS Completion of Share Purchase Plan-GSS.AX 30/09/16
GSS Full Year Statutory Accounts-GSS.AX 28/09/16
GSS Open Briefing - Capital Raising and Company Outlook-GSS.AX PRICE SENSITIVE28/09/16
GSS Clinical Validation of Sexual Health Detection Kit Commenced-GSS.AX PRICE SENSITIVE27/09/16
GSS Appendix 3B
27/03/19
GSS Change of Director's Interest Notice
22/03/19
GSS Appendix 3B
22/03/19
GSS Investor Presentation
15/03/19
GSS Change of Company Secretary and Registered Address
04/03/19
GSS Half Yearly Report and Accounts
25/02/19PRICE SENSITIVE
GSS Appendix 4C - quarterly
29/01/19PRICE SENSITIVE
GSS CE-IVD Mark for Respiratory Pathogen Detection Kit
17/12/18PRICE SENSITIVE
GSS Becoming a substantial holder
14/12/18
GSS $2.6m R&D refund received
07/12/18PRICE SENSITIVE
GSS Ceasing to be a substantial holder
07/12/18
GSS Becoming a substantial holder
05/12/18
GSS Change of Director's Interest Notice
03/12/18
GSS Appendix 3B
03/12/18
GSS Results of Annual General Meeting
29/11/18
GSS Chairman's Address to Shareholders
29/11/18PRICE SENSITIVE
GSS Withdrawal of resolution 4 from 2018 Annual General Meeting
29/11/18
GSS Investor presentation
26/11/18PRICE SENSITIVE
GSS Ceasing to be a substantial holder
22/11/18
GSS Becoming a substantial holder
21/11/18
GSS Appendix 3B
19/11/18
GSS Appendix 3B
15/11/18
GSS Notice of Annual General Meeting/Proxy Form
29/10/18
GSS 2018 Annual Report to Shareholders
29/10/18
GSS Appendix 4C - quarterly
29/10/18PRICE SENSITIVE
GSS Appendix 3B
22/10/18
GSS Appointment of CFO
22/10/18
GSS Date of 2018 AGM
17/09/18
GSS Appendix 4G and 2018 Corporate Governance Statement
28/08/18
GSS Appendix 4E and 2018 Financial Report
28/08/18PRICE SENSITIVE
GSS Additional Tax Incentive from understatement FY17 R&D Claim
23/08/18PRICE SENSITIVE
GSS Investor Presentation
15/08/18PRICE SENSITIVE
GSS Update to major customer contract announcement
03/08/18PRICE SENSITIVE
GSS Major Customer Contract Signed, New Kit and Instrument
02/08/18PRICE SENSITIVE
GSS Appendix 4C - quarterly
27/07/18PRICE SENSITIVE
GSS Investor Presentation
23/05/18PRICE SENSITIVE
GSS TGA registration for superbug detection kits
15/05/18PRICE SENSITIVE
GSS Investor Newsletter
07/05/18
GSS Positive Trial Results Presented at ECCMID
26/04/18PRICE SENSITIVE
GSS Appendix 4C - quarterly
26/04/18PRICE SENSITIVE
GSS European approval expands product suite
20/04/18
GSS Change of Director's Interest Notice
10/04/18
GSS Appendix 4D and Half Year Financial Statements
28/02/18PRICE SENSITIVE
GSS Appendix 4C - quarterly
25/01/18PRICE SENSITIVE
GSS Change of Director's Interest Notice
19/12/17
GSS Appendix 3B
11/12/17
GSS Change of Principal Place of Business address
11/12/17
GSS Results of 2017 AGM
28/11/17
GSS 2017 AGM Presentation
28/11/17PRICE SENSITIVE
GSS Clarification of Change in Substantial Shareholding
24/11/17
GSS Change in substantial holding
24/11/17
GSS Appendix 4C - quarterly
30/10/17PRICE SENSITIVE
GSS Notice of Annual General Meeting/Proxy Form
27/10/17
GSS Annual Report to shareholders
27/10/17
GSS Change of Director's Interest Notice
19/09/17
GSS Notification of 2017 AGM date
15/09/17
GSS Appendix 4G and 2017 Corporate Governance Statement
30/08/17
GSS Appendix 4E and 2017 Financial Report
30/08/17PRICE SENSITIVE
GSS Appendix 3B
02/08/17
GSS Investor Presentation
26/07/17
GSS Appendix 4C - quarterly
25/07/17PRICE SENSITIVE
GSS Appendix 3B
11/07/17
GSS Change of Director's Interest Notice
30/06/17
GSS Regulatory and Patent approval
20/06/17PRICE SENSITIVE
GSS Appendix 4C - quarterly
28/04/17PRICE SENSITIVE
GSS Results of Flavivirus Clinical Trial
24/04/17PRICE SENSITIVE
GSS Ceasing to be a substantial holder
31/03/17
GSS GSS Launches Sexually Transmitted Infection (STI) Kit
31/03/17PRICE SENSITIVE
GSS End of escrow period
15/03/17
GSS Change of Director's Interest Notice
10/03/17
GSS Appendix 4D - Half Yearly Report and Accounts
27/02/17PRICE SENSITIVE
GSS Appendix 3B
23/02/17
GSS Appendix 4C - quarterly
31/01/17PRICE SENSITIVE
GSS Change of Director's Interest Notice
22/12/16
GSS Appendix 3B
21/12/16
GSS Change of Director's Interest Notice
05/12/16
GSS Appendix 3B
30/11/16
GSS Results of Meeting
29/11/16
GSS 2016 AGM MD and CEO Presentation
29/11/16PRICE SENSITIVE
GSS Chairman's Address to Shareholders
29/11/16PRICE SENSITIVE
GSS Annual Report to shareholders-GSS.AX
28/10/16
GSS Notice of Annual General Meeting/Proxy Form-GSS.AX
28/10/16
GSS Appendix 4C - quarterly-GSS.AX
28/10/16PRICE SENSITIVE
GSS Change in substantial holding-GSS.AX
24/10/16
GSS Change in substantial holding-GSS.AX
24/10/16
GSS Change of Director's Interest Notice-GSS.AX
24/10/16
GSS Becoming a substantial holder-GSS.AX
20/10/16
GSS Cleansing Notice-GSS.AX
19/10/16
GSS Appendix 3B-GSS.AX
19/10/16
GSS STI Detection Kit Clinical Validation Trial Results-GSS.AX
18/10/16PRICE SENSITIVE
GSS Microcap Investment Conference Presentation-GSS.AX
18/10/16
GSS Results of EGM-GSS.AX
13/10/16
GSS Change in substantial holding-GSS.AX
11/10/16
GSS Change of Director's Interest Notice-GSS.AX
10/10/16
GSS Change of Director's Interest Notice-GSS.AX
10/10/16
GSS Appendix 3B - SPP allotment-GSS.AX
06/10/16
GSS Completion of Share Purchase Plan-GSS.AX
30/09/16
GSS Full Year Statutory Accounts-GSS.AX
28/09/16
GSS Open Briefing - Capital Raising and Company Outlook-GSS.AX
28/09/16PRICE SENSITIVE
GSS Clinical Validation of Sexual Health Detection Kit Commenced-GSS.AX
27/09/16PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
69.0¢ 		Change
-0.025(3.50%) 		Mkt cap ! $155.4M
Open High Low Value Volume
68.5¢ 69.0¢ 68.5¢ $13.72K 20.03K

Buyers (Bids)

No. Vol. Price($)
1 8524 69.0¢
 

Sellers (Offers)

Price($) Vol. No.
71.5¢ 3598 2
View Market Depth
Last trade - 15.44pm 15/11/2024 (20 minute delay) ?
GSS (ASX) Chart

Top Stories

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
HotCopper Highlights: Your most watched stocks for Week 46, 2024 What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.